Ensysce Biosciences Q3 Adj. EPS $(0.13) Misses $(0.12) Estimate, Sales $2.182M Beat $1.200M Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 89.92 percent increase over losses of $(1.29) per share from the same period last year. The company reported quarterly sales of $2.182 million which beat the analyst consensus estimate of $1.200 million by 81.80 percent. This is a 342.43 percent increase over sales of $493.104 thousand the same period last year.